Skin Disorders News

Tralokinumab significantly improved atopic dermatitis in adolescents, according to phase 3 trial results presented at the 2021 Fall Clinical Dermatology Conference.

Children with atopic dermatitis, but not those with psoriasis, were likely to be absent from school at least 15 days a year due to their condition, according to a study.

An extension study found atopic dermatitis patients continuously treated with tralokinumab had long-term improvement in severity and those with interrupted treatment matched improvement after 12 weeks.

Remibrutinib provided significant improvement in chronic spontaneous urticaria in a phase 2b dose affirming trial presented at the EADV virtual congress.

Patients with chronic urticaria appeared at an increased risk for obstructive sleep apnea, with higher disease activity correlating with greater risk, according to a study published in World Allergy Organization Journal.

Weekly dupilumab showed long-term safety and efficacy in atopic dermatitis patients in an open-label extension study presented at the EADV Congress virtual meeting.

Patients with mild to severe atopic dermatitis may benefit from long-term upadacitinib and topical corticosteroid treatment without any new safety risks, according to a study published in The Journal of Allergy and Clinical Immunology.

The FDA has approved Opzelura cream for the treatment of atopic dermatitis in non-immunocompromised patients, Incyte announced in a press release.

Health care workers with atopic dermatitis had greater irritation, dryness and other skin issues due to how frequently they washed their hands, according to a study published in Annals of Allergy, Asthma & Immunology.

Deficiencies in the CARMIL2 gene can lead to a variety of immunodeficiency complications, including cutaneous and respiratory allergies, necessitating clinician attention and further research, according to a study published in Allergy.